The high hydrostatic pressure processing of donor milk may better protect preterm infants from gut and liver pathologies compared to Holder pasteurization, which is currently used in most human milk banks.
The discovery of intestinal actors, such as enterosynes, able to modulate the ENS-induced duodenal contraction is an innovative approach. Among all the intestinal factors, the understanding of the role of gut microbes in controlling glycaemia remains a major target. For instance, we researched and demonstrated how the modulation of gut microbiota by prebiotics could permit the identification of novel enterosynes.
Targeting the enteric nervous system that controls gut motility is now considered as an innovative therapeutic way in T2D to limit intestinal glucose absorption and restore the gut‐brain axis to improve insulin sensitivity. So far, little is known about the role of glucose on duodenal contraction in fasted and fed states in normal and diabetic conditions.
Currently, the gut is considered a primary site for the development of pathologies that modify brain functions such as neurodegenerative (Parkinson’s, Alzheimer’s, etc.) and metabolic (type 2 diabetes, obesity, etc.) disorders. Deciphering the mode of interaction between microbiota and the brain is a real original option to prevent (and maybe treat in the future) the establishment of gut-brain disfunctions and associated pathologies.
The Amazonian forests are home to a shrub, the camu-camu, whose fruit could be of great help in the fight against obesity and metabolic diseases. This is described in our latest study published with the A-Mansia R&D team in the journal Metabolites.
Human breast milk donated to human milk banks is the sole diet for preterm infants when maternal BM is not available. Pasteurization of donated breast milk is an essential step to inactivate pathogens to ensure microbial safety for preterm babies. The study of intestinal motility can be used to optimize pasteurization processes.
The enteric nervous system (ENS) plays a key role in controlling the gut-brain axis under normal and pathological conditions, such as type 2 diabetes. The discovery of intestinal actors, such as enterosynes, able to modulate the ENS-induced duodenal contraction is considered a pioneering approach.
In addition to their classical mode of action in the brain, circulating factors may modulate the release of reactive oxygen/nitrogen species (ROS/RNS) from endothelial cells that compose the blood-brain-barrier without entering the brain. Due to their high capacity to diffuse across membranes, ROS/RNS can reach neurons and modify their activity. This study investigates other mechanisms of actions in which beta-blockers may display a central effect without crossing the blood brain barrier.
Targeting the Enteric Nervous System to Treat Metabolic Disorders? “Enterosynes” as Therapeutic Gut Factors
The gut-brain axis is of crucial importance for controlling glucose homeostasis. Alteration of this axis promotes the type 2 diabetes phenotype. Recently, a new concept has emerged to demonstrate the crucial role of the enteric nervous system in the control of glycaemia via the hypothalamus.
Enterosys provides in vitro models closer to physiology for dermo cosmetic applications.
The preclinical services platform SkinObs dedicated to dermocosmetics describes Enterosys’ innovative approach to evaluate the antioxidant capacity of active ingredients
Question about the contribution of Gut and Gut-organs axis to your preclinical studies and innovation portfolio ?
Our team of experts will be happy to answer all your questions and discuss with you to guide you in the design of an optimized protocol to meet your objectives and add value to your molecules with quick and concrete solutions.